Trial Profile
Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 04 Dec 2018 Status changed from recruiting to discontinued.
- 17 Jan 2015 New trial record